|
|
Vaccine Detail
|
Brucella abortus Omp16 L7/L12 Omp19 SOD recombinant influenza viral vector vaccine |
| Vaccine Information |
- Vaccine Name: Brucella abortus Omp16 L7/L12 Omp19 SOD recombinant influenza viral vector vaccine
- Target Pathogen: Brucella spp.
- Target Disease: Brucellosis
- Vaccine Ontology ID: VO_0009385
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Sheep
- Antigen: Omp16; L7/L12; Omp19; SOD | Omp16; L7/L12; Omp19; Cu-Zn superoxide dismutase (SOD)
-
Adjuvant:
Montanide Gel01 | 20% Montanide Gel01
- Preparation: Influenza viral vector expressing Brucella abortus proteins Omp16, L7/L12, Omp19, and SOD; administered thrice at 21-day intervals with 20% Montanide Gel01 adjuvant via simultaneous subcutaneous and conjunctival routes. (Mailybayeva et al, 2017)
Vaccine administered thrice concurrently via subcutaneous and conjunctival routes at 21-day intervals; control group received 20% Montanide Gel01 adjuvant in phosphate-buffered saline. (Mailybayeva et al, 2020)
- Description: The Flu-BA vaccine was improved by adding two additional proteins (Omp19 and SOD) and modifying the immunization method to maximize efficacy and safety. Efficacy: Prevented abortion in 66.7% of pregnant sheep and 77.8% of pregnant goats; complete protection (absence of live B. melitensis 16M) in 55.6% of sheep and 66.7% of goats; protection of fetuses in 72.7% of lambs and 90.0% of yeanlings; significantly reduced infection severity and colonization compared to controls; protection parameters comparable to commercial B. melitensis strain Rev. 1 vaccine. Immune response: Induced antigen-specific IgG antibodies predominantly of IgG2a isotype and also IgG1; strong lymphocyte recall response with IFN-γ production detected at 42 days post-vaccination. (Mailybayeva et al, 2017)
The study evaluated an improved commercial Brucella abortus vaccine based on influenza viral vectors expressing Brucella immunodominant proteins, with improved formulation and route of administration. Efficacy: Protection levels against B. melitensis 16M infection were 0-20% in sheep and 20-40% in goats over 6 months; infection severity and Brucella colonization significantly reduced in vaccinated animals compared to controls. Immune response: Induced antigen-specific Th1-biased antibody response (IgG2a over IgG1), T-cell and interferon γ responses lasting over 1 month post-last vaccination. (Mailybayeva et al, 2020)
|
| Host Response |
|
|
| References |
Mailybayeva et al, 2017: Mailybayeva A, Yespembetov B, Ryskeldinova S, Zinina N, Sansyzbay A, Renukaradhya GJ, Petrovsky N, Tabynov K. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats. PloS one. 2017; 12(10); e0186484. [PubMed: 29023541].
Mailybayeva et al, 2020: Mailybayeva A, Ryskeldinova S, Zinina N, Zhou EM, Renukaradhya GJ, Tabynov K. Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector-Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats. Frontiers in veterinary science. 2020; 7; 58. [PubMed: 32175335].
|
|
